Lilly's Orforglipron Excels in Phase 3 Trials for Type 2 Diabetes
TL;DR
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, showed superior glycemic control in two Phase 3 trials, outperforming dapagliflozin and oral semaglutide, with significant A1C reductions and weight loss, supporting its potential as a new standard treatment for type 2 diabetes.
Topics:businesshealthcare#glycemic-control#healthcare#lilly#orforglipron#phase-3-trials#type-2-diabetes
Want the full story? Read the original reporting
Read on investor.lilly.com